Presbyopia - Market Insight, Epidemiology, and Market Forecast - 2036

Presbyopia Insights and Trends

• According to DelveInsight's analysis, Presbyopia market size was found to be ~USD 11,000 million in the leading markets (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• A majority (~3/4th cases) of the presbyopia patients are using the eyeglasses for correction of close-up vision problems. In terms of revenue as well, eyeglasses are contributing around 50% of the USA market in 2022.
• Two companies are currently evaluating the role of their products in the late stage (i.e. Pre-registration and Phase III) of development for the treatment of presbyopia. Opus Genetics/Viatris with Phentolamine, Eyenovia with MicroLine (Pilocarpine). Glaukos Corporation is also in the race with GLK-302 which is currently in Phase II.
• The presbyopia market is undergoing a structural shift from traditional corrective devices toward pharmacologic innovation, with VUITY (pilocarpine 1.25%) establishing itself as the category pioneer. As the first FDA-approved eye drop for presbyopia, VUITY leveraged strong Phase III data, once-daily dosing convenience, and aggressive early market education to secure leadership in the mild-to-moderate segment.
• Building on the validation created by VUITY, YUVEZZI is positioned to emerge as a key follow-on competitor, capitalizing on growing awareness of pharmacologic correction. With differentiation in formulation and comparable efficacy expectations, it is anticipated to capture meaningful share within the expanding miotic segment.
• VIZZ is expected to benefit from overall class expansion dynamics as more patients and physicians adopt eye drops as a viable alternative to reading glasses. However, its later entry may moderately limit peak penetration relative to earlier branded therapies.
• In the 7MM, the total age-specific cases of Presbyopia were 66,880,000, 76,000,000, 55,650,000, and 35,000,000 for the age group less than 60 years, 60-69 years, 70-79 years, and =80 years respectively, in the year 2022.
• In the 7MM, the total Gender-specific cases of Presbyopia were 99,700,000 and 114,000,000 for males and females, respectively in the year 2022.

Presbyopia Market Size and Forecast

• 2025 PRESBYOPIA Market Size: ~USD 11,000 million
• 2036 Projected PRESBYOPIA Market Size: ~USD 18,000 million
• PRESBYOPIA Growth Rate (2026-2036): 4.9% CAGR

DelveInsight's 'Presbyopia - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the PRESBYOPIA, historical and forecasted epidemiology, as well as the PRESBYOPIA market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Presbyopia market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, PRESBYOPIA patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in PRESBYOPIA and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Presbyopia Understanding and Treatment Algorithm

Presbyopia Overview and Diagnosis

Presbyopia is a common age-related condition that progressively reduces the eye's ability to focus on near objects, typically affecting individuals over the age of 40. It results from structural and physiological changes in the eye, particularly the stiffening of the crystalline lens and reduced efficiency of the accommodative mechanism involving the ciliary body and zonular fibers. The onset and progression of presbyopia may vary based on factors such as refractive status, environmental exposure (e.g., UV light), and systemic conditions like diabetes, with hyperopic individuals often experiencing symptoms earlier than myopic individuals. As the global population ages, presbyopia has become an increasingly significant public health concern, affecting over one billion people worldwide and driving the need for effective diagnostic approaches and both nonsurgical and surgical treatment strategies.

Diagnosis largely depends on the near focusing distance required for daily tasks and the assessment of amplitude of accommodation (AoA), which represents the maximum optical power the eye can generate when shifting focus from distant to near objects. AoA is commonly measured using clinical methods such as the push-up and push-down techniques, where a near target is moved closer to or farther from the eye until blur or clear vision is reported, as well as the minus lens technique, which increases accommodative demand using incremental negative lenses while viewing a distant chart. Retinoscopy may also be used as an objective method to evaluate accommodative changes without relying on patient responses, although it requires significant clinical expertise.

Current Presbyopia Treatment Landscape

Treatment options include non-surgical and surgical strategies tailored to a patient's visual needs, refractive status, ocular health, and lifestyle. Non-surgical management involves spectacles (single-vision, bifocal, and progressive lenses), contact lenses (monovision or multifocal designs), and pharmacological therapies that improve depth of focus through miosis or lens modifications using agents such as pilocarpine, carbachol, aceclidine, and phentolamine. Surgical options include corneal procedures such as LASIK or PRK-based monovision, presbyLASIK for corneal multifocality, and intracorneal inlays that enhance near vision via a pinhole effect. Lens-based approaches include refractive lens exchange or cataract surgery with intraocular lens (IOL) implantation, such as monofocal, extended depth-of-focus (EDOF), accommodating, or phakic IOLs, while scleral expansion procedures aim to restore accommodative amplitude but have limited clinical adoption. Emerging technologies, including small incision lenticule extraction (SMILE) and noninvasive laser procedures such as Opti-K, are also being explored as potential alternatives for presbyopia management.

Presbyopia Unmet Needs

The section "unmet needs of Presbyopia" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Inconsistent Access to Affordable, Effective Vision Correction

2. Limitations of Current Treatment Options and Lack of Personalized Solutions

3. Insufficient Integration of functional and QoL

4. Lack of Early Detection and Proactive Presbyopia Screening, and others.....

Presbyopia Epidemiology

Key Findings from PRESBYOPIA Epidemiological Analysis and Forecast

• According to DelveInsight's estimates, the total number of prevalent cases of Presbyopia in the 7MM was nearly 290,000 cases in 2025 and is projected to increase during the forecasted period.
• The total number of prevalent cases of Presbyopia in the United States was nearly 120,000 in 2025.
• Presbyopia shows a slight female predominance and is most common in individuals aged 60-69 years.

Presbyopia Drug Analysis & Competitive Landscape

The Presbyopia drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I/II-II clinical trials. It covers mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, strategic partnerships upcoming Key catalyst for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the Presbyopia treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the Presbyopia therapeutics market.

Approved Therapies for PRESBYOPIA

VUITY (Pilocarpine HCI): Abbvie

VUITY(R) (pilocarpine HCl ophthalmic solution) 1.25%, developed by Allergan, an AbbVie company, is a once-daily prescription eye drop approved by the US FDA for the treatment of presbyopia (age-related near vision impairment) in adults. It is an optimized formulation of pilocarpine designed to enhance near and intermediate vision without compromising distance vision by leveraging the eye's natural mechanism of pupil constriction. The formulation incorporates proprietary pHast(TM) technology, which enables rapid adjustment to the physiological pH of the tear film, facilitating efficient drug delivery. Approval of VUITY was supported by results from the Phase III GEMINI 1 and GEMINI 2 clinical trials, which demonstrated significant improvement in near vision with favorable tolerability. As the first eye drop of its kind for presbyopia, VUITY offers a non-invasive therapeutic alternative to traditional reading glasses.

Presbyopia Pipeline Analysis

MicroLine (Pilocarpine Ophthalmic): Eyenovia

MicroLine is MicroLine, a patented pilocarpine-based therapy developed by Eyenovia for the treatment of presbyopia. Pilocarpine is a well-established ophthalmic agent known to enhance depth of focus, thereby helping counteract age-related loss of accommodation and improving near vision. However, conventional pilocarpine eye drops may be limited by dose-related side effects and variability associated with traditional eyedropper administration. To address these challenges, MicroLine is delivered using the Optejet dispenser, which administers a precise microdose, approximately one-fifth the volume of a standard eye drop, allowing more accurate, consistent, and convenient drug delivery. MicroLine (pilocarpine ophthalmic) has been evaluated in Phase III clinical trials for the treatment of presbyopia.

Presbyopia Key Players, Market Leaders and Emerging Companies

• Abbvie
• Orasis pharmaceuticals
• Tentpoint Therapeutics
• Opus Genetics/Viatris
• Glaukos Corporation Akeso Biopharma
• Summit Therapeutics , and others

Presbyopia Drug Updates

• Tenpoint Therapeutics announced that the US Food and Drug Administration (FDA) approved YUVEZZ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, previously known as BRIMOCHOL(TM) PF, the first and only dual-agent eye drop for the treatment of presbyopia in adults in January 2026.
• In January 2026, Tenpoint Therapeutics announced it has secured USD 235 million through the successful close of its Series B preferred stock financing and a credit facility. The financing will help in the commercialization of YUVEZZ.
• In February 2025, Opus Genetics announced completion of enrollment in the VEGA-3 Phase III clinical trial evaluating Phentolamine Ophthalmic Solution 0.75% for presbyopia.

Presbyopia Market Outlook

Presbyopia is an age-related condition characterized by the gradual loss of flexibility of the eye's natural lens, leading to a reduced ability to focus on near objects. It commonly becomes noticeable between the ages of 40 and 50 and represents a normal part of the aging process. Without appropriate correction, presbyopia can result in significant visual impairment, affecting daily tasks, workplace productivity, and overall quality of life. Management focuses on compensating for the eye's diminished near-focusing ability rather than curing the condition. While presbyopia cannot be reversed, appropriately prescribed glasses or contact lenses can significantly improve near vision and enhance visual comfort during close-range activities. Current treatment options for presbyopia include surgical options like refractive surgery, lens implant, corneal inlays, non-surgical options like optical correction spectacles and contact lenses etc. and the use of pharmacological treatment.

In October 2021, the US FDA approved the VUITY (pilocarpine HCl ophthalmic solution) 1.25% for the treatment of presbyopia, commonly known as age-related blurry near vision, in adults. VUITY is a once-daily prescription eye drop and the first FDA-approved pharmacological treatment specifically indicated for presbyopia. It is an optimized formulation of pilocarpine designed to improve near and intermediate vision without compromising distance vision by utilizing the eye's natural ability to reduce pupil size, thereby increasing depth of focus and enhancing visual clarity for near tasks.

In October 2023, the US FDA approved QLOSI(TM) (pilocarpine hydrochloride ophthalmic solution) 0.4% for the treatment of presbyopia in adults. QLOSI is an innovative, low-dose, preservative-free pilocarpine eye drop developed to improve near vision by modulating pupil size and creating a pinhole effect that increases depth of focus. This mechanism enhances near visual acuity and supports clearer vision for close-range tasks while maintaining comfort, efficacy, and safety through its specially designed formulation. As a non-invasive pharmacological option, QLOSI provides an alternative approach for the management of age-related loss of near vision in adults.

Companies, including Eyenovia, Glaukos Corporation, and others, are investigating potential drug candidates that can significantly change the market landscape during the forecast period. Approaches include Cholinergic Muscarinic receptor agonists (Microline and GLK-302) and others.

• In 2025, the United States held the largest market share for Presbyopia among the 7MM, accounting for approximately 50% of the total market.
• In 2025, Non-Surgical treatment particularly the eye glasses led the US Presbyopia treatment market and is projected to retain its position as the dominant market leader through 2036.
• In 2025, Eye drops treatment for Presbyopia generated approximately USD 3,000 million in revenue across the 7MM countries.

Drug Class/Insights into Leading Emerging and Marketed Therapies in PRESBYOPIA (2022-2036 Forecast)

The Presbyopia market comprises of different mechanism class, including Cholinergic Muscarinic receptor agonist and Alpha 1 and Alpha 2 adrenergic receptor antagonists, each designed to target distinct inflammatory pathways underlying disease pathophysiology.

• Cholinergic Muscarinic receptor agonist: Pilocarpine hydrochloride is a cholinergic muscarinic agonist that stimulates muscarinic receptors in smooth muscles, particularly the iris sphincter and ciliary muscles of the eye. By activating these receptors, it induces contraction of the iris sphincter muscle, resulting in pupil constriction that enhances near and intermediate visual acuity while preserving some responsiveness to light. Additionally, contraction of the ciliary muscle may shift the eye toward a slightly myopic state, further supporting improved near vision. Some approved drugs with this mechanism of action for presbyopia are VUITY (Abbvie), QLOSI (Orasis Pharmaceuticals) and more.
• Alpha 1 and Alpha 2 adrenergic receptor antagonists: Pupil dilation is primarily regulated by the radial iris dilator muscles that surround the pupil, which are activated through a1-adrenergic receptors. Phentolamine acts by reversibly binding to these receptors on the iris dilator muscle, leading to a reduction in pupil diameter. It directly counteracts the mydriatic effects of a1-adrenergic agonists and indirectly reverses mydriasis caused by muscarinic antagonists acting on the iris sphincter muscle.

Presbyopia Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the PRESBYOPIA drug's uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

The Presbyopia market shows a clear uptake split between established therapies and newer targeted agents. Cholinergic muscarinic receptor agonists have demonstrated moderate adoption due to their non-invasive mechanism that enhances near vision by inducing pupillary constriction and increasing depth of focus. However, uptake remains gradual owing to the temporary nature of their efficacy and tolerability concerns associated with pilocarpine-based miotics. In contrast, alpha-1 and alpha-2 adrenergic receptor antagonists are expected to support future uptake by reducing pupil diameter through adrenergic blockade rather than direct ciliary muscle stimulation, potentially improving tolerability and expanding the pharmacological treatment options for presbyopia. Emerging pipeline agents are expected to experience more gradual adoption as clinical evidence matures and guideline integration evolves.

Detailed insights of emerging therapies' drug uptake is included in the report

Market Access and Reimbursement of Approved therapies in Presbyopia

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

The United States

VUITY

The My VUITY(R) Points (MVP) program is a manufacturer-sponsored patient support initiative designed to improve affordability and encourage continued use of VUITY(R) (pilocarpine HCl ophthalmic solution 1.25%) among eligible patients in the United States. The program allows patients to earn reward points with eligible prescription fills, which can later be redeemed for discounts or free product supplies, helping to reduce out-of-pocket expenses. It is intended to support patient access in a treatment category where insurance reimbursement may be limited or variable, particularly as pharmacological therapies for presbyopia continue to emerge.

The program primarily targets commercially insured or cash-paying patients and is not available to individuals enrolled in federal, state, or other government-funded insurance programs, including Medicare, Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs, or where prohibited by law or by the patient's health insurance provider. By lowering financial barriers and promoting adherence, the MVP program supports early market adoption and sustained therapy use. It functions as a market access support mechanism rather than a formal reimbursement program, as it operates independently of payer coverage decisions. The program also includes specific eligibility criteria and may be modified or discontinued by the manufacturer at its discretion.

Reimbursement is a crucial factor that affects the drug's access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

NOTE: Further Details are provided in the final report....

Presbyopia Therapies Price Scenario & Trends

Pricing and analogue assessment of Presbyopia therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most approproiate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

• Pricing of Presbyopia treatment options

Non-surgical optical correction remains the primary approach for managing presbyopia, with eyeglasses being the most accessible and widely used option at an average annual cost of around USD 100. Contact lenses, costing approximately USD 200 per year, involve recurring expenses for supplies, maintenance, and routine eye care. Over-the-counter eye drops, priced at about USD 80 annually, provide only symptomatic relief and serve as adjuncts rather than effective corrective treatments.

Industry Experts and Physician Views for Presbyopia

To keep up with Presbyopia market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the Presbyopia emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in PRESBYOPIA, including MD, Ph.D, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 15+ KOLs to gather insights at country level. Centers such as the Clinical Professor of Ophthalmology, New York University Medicine, Ophthalmologist, Harvard Eye Associates and Associate Professor, University of Pikeville,etc. were contacted. Their opinion helps understand and validate current and emerging Presbyopia therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in Presbyopia.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of PRESBYOPIA, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of Presbyopia, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Presbyopia market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Presbyopia market.

Report Insights

• Presbyopia Patient Population Forecast
• Presbyopia Therapeutics Market Size
• Presbyopia Pipeline Analysis
• Presbyopia Market Size and Trends
• Presbyopia Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-enabled Market Research Report
• 11-year forecast
• Presbyopia Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (by geography)
• Presbyopia Treatment Addressable Market (TAM)
• Presbyopia Competitive Landscape
• Presbyopia Major Companies Insights
• Presbyopia Price Trends and Analogue Assessment
• Presbyopia Therapies Drug Adoption/Uptake
• Presbyopia Therapies Peak Patient Share Analysis

Report Assessment

• Presbyopia Current Treatment Practices
• Presbyopia Unmet Needs
• Presbyopia Clinical Development Analysis
• Presbyopia Emerging Drugs Product Profiles
• Presbyopia Market Attractiveness
• Presbyopia Qualitative Analysis (SWOT and conjoint analysis)

FAQs:

Market Insights

• What was the Presbyopia market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of Presbyopia?
• What impact will patent expiry have on the Presbyopia therapy market?
• What are the disease risks, burdens, and unmet needs of Presbyopia? What will be the growth opportunities across the 7MM concerning the patient population with Presbyopia?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of Presbyopia? What are the current guidelines for treating Presbyopia in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Presbyopia market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.